{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:12:18Z","timestamp":1787314338735,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Whether Hashimoto\u2019s thyroiditis (HT) affects the lymph node metastasis of papillary thyroid carcinoma (PTC) remains uncertain. The diagnostic criteria for HT differed in previous studies. Our study focused on analysing the influence of HT on PTC lymph node metastasis (LNM) with stringent diagnostic criteria for HT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 444 patients diagnosed with PTC from 2019 to 2020 were enrolled and divided into\u00a0two groups: HT group and non-HT group. Diagnostic criteria of HT were as follows: thyroid peroxidase antibody (+) and postoperative histopathology of Hashimoto\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There was no significant difference in the LNM rate between HT group and non-HT group. Patients in the HT group had fewer numbers of metastatic LNs and lower metastatic LNs ratio in central region. In the HT group, age\u2009&lt;\u200955 and tumor size \u226510\u2009mm were independent risk factors for central LNM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The autoimmune response of HT seems to reduce the central lymph node metastasis of HT PTCs. Age\u2009&lt;\u200955 and tumor size \u226510\u2009mm were independent risk factors of central lymph node metastasis in HT PTCs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-021-00923-2","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T17:03:02Z","timestamp":1641402182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Lymph node metastasis of papillary thyroid carcinoma in the context of Hashimoto\u2019s thyroiditis"],"prefix":"10.1186","volume":"22","author":[{"given":"Lirong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"923_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"923_CR2","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388:2783\u201395.","journal-title":"Lancet"},{"key":"923_CR3","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2017.2719","volume":"317","author":"H Lim","year":"2017","unstructured":"Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317:1338\u201348.","journal-title":"JAMA."},{"key":"923_CR4","doi-asserted-by":"publisher","first-page":"102950","DOI":"10.1016\/j.critrevonc.2020.102950","volume":"150","author":"V Marotta","year":"2020","unstructured":"Marotta V, Malandrino P, Russo M, Panariello I, Ionna F, Chiofalo MG, et al. Fathoming the link between anthropogenic chemical contamination and thyroid cancer. Crit Rev Oncol Hematol. 2020;150:102950.","journal-title":"Crit Rev Oncol Hematol"},{"key":"923_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.chemosphere.2018.11.084","volume":"218","author":"V Marotta","year":"2019","unstructured":"Marotta V, Russo G, Gambardella C, Grasso M, La Sala D, Chiofalo MG, et al. Human exposure to bisphenol AF and diethylhexylphthalate increases susceptibility to develop differentiated thyroid cancer in patients with thyroid nodules. Chemosphere. 2019;218:885\u201394.","journal-title":"Chemosphere."},{"key":"923_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1677\/erc.0.0090227","volume":"9","author":"EL Mazzaferri","year":"2002","unstructured":"Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer. 2002;9:227\u201347.","journal-title":"Endocr Relat Cancer"},{"key":"923_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jso.23967","volume":"112","author":"FH Liu","year":"2015","unstructured":"Liu FH, Kuo SF, Hsueh C, Chao TC, Lin JD. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis. J Surg Oncol. 2015;112:149\u201354.","journal-title":"J Surg Oncol"},{"key":"923_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fendo.2020.00265","volume":"11","author":"J Mao","year":"2020","unstructured":"Mao J, Zhang Q, Zhang H, Zheng K, Wang R, Wang G. Risk factors for lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2020;11:265.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"923_CR9","doi-asserted-by":"publisher","first-page":"979167","DOI":"10.1155\/2015\/979167","volume":"2015","author":"A Pyzik","year":"2015","unstructured":"Pyzik A, Grywalska E, Matyjaszek-Matuszek B, Roli\u0144ski J. Immune disorders in Hashimoto's thyroiditis: what do we know so far? J Immunol Res. 2015;2015:979167.","journal-title":"J Immunol Res"},{"key":"923_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.autrev.2014.01.007","volume":"13","author":"P Caturegli","year":"2014","unstructured":"Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13:391\u20137.","journal-title":"Autoimmun Rev"},{"key":"923_CR11","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.3390\/ijms20184413","volume":"20","author":"SM Ferrari","year":"2019","unstructured":"Ferrari SM, Fallahi P, Galdiero MR, Ruffilli I, Elia G, Ragusa F, et al. Immune and inflammatory cells in thyroid cancer microenvironment. Int J Mol Sci. 2019;20:4413.","journal-title":"Int J Mol Sci"},{"key":"923_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s12020-017-1401-7","volume":"58","author":"CT Shen","year":"2017","unstructured":"Shen CT, Zhang XY, Qiu ZL, Sun ZK, Wei WJ, Song HJ, et al. Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword? Endocrine. 2017;58:176\u201383.","journal-title":"Endocrine."},{"key":"923_CR13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s12020-013-0121-x","volume":"46","author":"X Wu","year":"2014","unstructured":"Wu X, Lun Y, Jiang H, Gang Q, Xin S, Duan Z, et al. Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer. Endocrine. 2014;46:554\u201360.","journal-title":"Endocrine."},{"key":"923_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1556\/650.2017.30647","volume":"158","author":"S Moln\u00e1r","year":"2017","unstructured":"Moln\u00e1r S, Gy\u0151ry F, Nagy E, M\u00e9hes G, Moln\u00e1r C. Clinico-pathological features of papillary thyroid cancer coexistent with Hashimoto\u2019s thyroiditis. Orv Hetil. 2017;158:178\u201382.","journal-title":"Orv Hetil"},{"key":"923_CR15","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1007\/s00268-019-05337-9","volume":"44","author":"I Lee","year":"2020","unstructured":"Lee I, Kim HK, Soh EY, Lee J. The association between chronic lymphocytic thyroiditis and the progress of papillary thyroid cancer. World J Surg. 2020;44:1506\u201313.","journal-title":"World J Surg"},{"key":"923_CR16","first-page":"1","volume":"33","author":"P Del Rio","year":"2008","unstructured":"Del Rio P, Cataldo S, Sommaruga L, Concione L, Arcuri MF, Sianesi M. The association between papillary carcinoma and chronic lymphocytic thyroiditis: does it modify the prognosis of cancer? Minerva Endocrinol. 2008;33:1\u20135.","journal-title":"Minerva Endocrinol"},{"key":"923_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3322\/caac.21439","volume":"68","author":"ND Perrier","year":"2018","unstructured":"Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2018;68:55\u201363.","journal-title":"CA Cancer J Clin"},{"key":"923_CR18","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/hed.21594","volume":"33","author":"SS Kim","year":"2011","unstructured":"Kim SS, Lee BJ, Lee JC, Kim SJ, Jeon YK, Kim MR, et al. Coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma: the influence of lymph node metastasis. Head Neck. 2011;33:1272\u20137.","journal-title":"Head Neck"},{"key":"923_CR19","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00432-014-1629-z","volume":"140","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Dai J, Wu T, Yang N, Yin Z. The study of the coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma. J Cancer Res Clin Oncol. 2014;140:1021\u20136.","journal-title":"J Cancer Res Clin Oncol"},{"key":"923_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00423-012-1021-x","volume":"398","author":"A Konturek","year":"2013","unstructured":"Konturek A, Barczy\u0144ski M, Wierzchowski W, Stopa M, Nowak W. Coexistence of papillary thyroid cancer with Hashimoto thyroiditis. Langenbeck's Arch Surg. 2013;398:389\u201394.","journal-title":"Langenbeck's Arch Surg"},{"key":"923_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/hed.21518","volume":"33","author":"KW Kim","year":"2011","unstructured":"Kim KW, Park YJ, Kim EH, Park SY, Park DJ, Ahn SH, et al. Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis. Head Neck. 2011;33:691\u20135.","journal-title":"Head Neck"},{"key":"923_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1530\/ERC-17-0085","volume":"24","author":"V Marotta","year":"2017","unstructured":"Marotta V, Sciammarella C, Chiofalo MG, Gambardella C, Bellevicine C, Grasso M, et al. Hashimoto\u2019s thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. Endocr Relat Cancer. 2017;24:485\u201393.","journal-title":"Endocr Relat Cancer"},{"key":"923_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.14639\/0392-100X-1709","volume":"37","author":"J Liang","year":"2017","unstructured":"Liang J, Zeng W, Fang F, Yu T, Zhao Y, Fan X, et al. Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients. Acta Otorhinolaryngol Ital. 2017;37:393\u2013400.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"923_CR24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3389\/fimmu.2017.00521","volume":"8","author":"E Fr\u00f6hlich","year":"2017","unstructured":"Fr\u00f6hlich E, Wahl R. Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases. Front Immunol. 2017;8:521.","journal-title":"Front Immunol"},{"key":"923_CR25","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3904\/kjim.2018.289","volume":"33","author":"K Jo","year":"2018","unstructured":"Jo K, Lim DJ. Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer. Korean J Intern Med. 2018;33:1050\u20137.","journal-title":"Korean J Intern Med"},{"key":"923_CR26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1177\/0194599820904923","volume":"162","author":"SN Amin","year":"2020","unstructured":"Amin SN, Shinn JR, Naguib MM, Netterville JL, Rohde SL. Risk factors and outcomes of postoperative recurrent well-differentiated thyroid cancer: a single institution\u2019s 15-year experience. Otolaryngol Head Neck Surg. 2020;162:469\u201375.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"923_CR27","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s41598-019-55991-1","volume":"10","author":"LH Jiang","year":"2020","unstructured":"Jiang LH, Yin KX, Wen QL, Chen C, Ge MH, Tan Z. Predictive risk-scoring model for central lymph node metastasis and predictors of recurrence in papillary thyroid carcinoma. Sci Rep. 2020;10:710.","journal-title":"Sci Rep"},{"key":"923_CR28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1186\/s12885-019-5835-6","volume":"19","author":"C Liu","year":"2019","unstructured":"Liu C, Xiao C, Chen J, Li X, Feng Z, Gao Q, et al. Risk factor analysis for predicting cervical lymph node metastasis in papillary thyroid carcinoma: a study of 966 patients. BMC Cancer. 2019;19:622.","journal-title":"BMC Cancer"},{"key":"923_CR29","doi-asserted-by":"publisher","first-page":"R499","DOI":"10.1530\/ERC-16-0372","volume":"23","author":"V Marotta","year":"2016","unstructured":"Marotta V, Sciammarella C, Colao A, Faggiano A. Application of molecular biology of differentiated thyroid cancer for clinical prognostication. Endocr Relat Cancer. 2016;23:R499\u2013r515.","journal-title":"Endocr Relat Cancer"},{"key":"923_CR30","first-page":"661","volume":"102","author":"V Marotta","year":"2017","unstructured":"Marotta V, Sciammarella C, Capasso M, Testori A, Pivonello C, Chiofalo MG, et al. Germline polymorphisms of the VEGF pathway predict recurrence in nonadvanced differentiated thyroid cancer. J Clin Endocrinol Metab. 2017;102:661\u201371.","journal-title":"J Clin Endocrinol Metab"},{"key":"923_CR31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/jso.24713","volume":"116","author":"JL Roh","year":"2017","unstructured":"Roh JL, Park JW, Jeong J, Gong G, Cho KJ, Choi SH, et al. Extranodal extension of lymph node metastasis as a prognostic indicator of recurrence and survival in papillary thyroid carcinoma. J Surg Oncol. 2017;116:450\u20138.","journal-title":"J Surg Oncol"},{"key":"923_CR32","doi-asserted-by":"publisher","first-page":"13361","DOI":"10.1038\/s41598-019-50069-4","volume":"9","author":"J Lee","year":"2019","unstructured":"Lee J, Lee SG, Kim K, Yim SH, Ryu H, Lee CR, et al. Clinical value of lymph node ratio integration with the 8(th) edition of the UICC TNM classification and 2015 ATA risk stratification systems for recurrence prediction in papillary thyroid cancer. Sci Rep. 2019;9:13361.","journal-title":"Sci Rep"},{"key":"923_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1530\/EJE-20-0131","volume":"183","author":"J Lee","year":"2020","unstructured":"Lee J, Kim CH, Min IK, Jeong S, Kim H, Choi MJ, et al. Detailed characterization of metastatic lymph nodes improves the prediction accuracy of currently used risk stratification systems in N1 stage papillary thyroid cancer. Eur J Endocrinol. 2020;183:83\u201393.","journal-title":"Eur J Endocrinol"},{"key":"923_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40425-018-0483-y","volume":"7","author":"S Imam","year":"2019","unstructured":"Imam S, Dar P, Paparodis R, Almotah K, Al-Khudhair A, Hasan SA, et al. Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer. J Immunother Cancer. 2019;7:3.","journal-title":"J Immunother Cancer"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00923-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-021-00923-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00923-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T17:03:11Z","timestamp":1641402191000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00923-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["923"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00923-2","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]},"assertion":[{"value":"22 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were performed in accordance with declaration of Helsinki. Due to the limitations of retrospective study, we did not obtain informed consent from patients. The Institutional Review Board of Xi\u2019an Jiaotong University Second Affiliated Hospital had approved this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare no conflicts of interest for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}